|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 273.5 TWD | -1.97% |
|
-8.22% | +30.55% |
| Mar. 14 | Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 07 | Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan | CI |
The patent, KETAMINE PAMOATE AND USE THEREOF, applied by Alar Pharmaceuticals Inc. has received notice of allowance from United States Patent and Trademark Office (USPTO). Granding above patent by the Company will facilitate the international licensing business. It takes a considerable time to develop a new drug and the cost of development is relatively high.
The success of the development is not guaranteed. The investors shall bear the investment risk and judge the investment with caution.
| 1st Jan change | Capi. | |
|---|---|---|
| +30.55% | 560M | |
| +3.37% | 69.25B | |
| +12.55% | 9B | |
| -12.75% | 4.96B | |
| +42.38% | 4.47B | |
| +5.23% | 3.9B | |
| +19.58% | 2.45B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B |
ALAR PHARMACEUTICALS INC. 
